Biomarkers Consortium

FNIH Biomarkers Consortium


Identification and Validation of ctDNA Quality Control Materials

The project will develop tools to enable clinicians to measure and confidently compare circulating tumor DNA (ctDNA) test results across different laboratories.

Biomarkers Consortium Neuroscience Symposium

During the symposium, there were five sessions that touched on the following topics: Multimodal biomarkers, fluid biomarkers, imaging biomarkers, EEG biomarkers and clinical measures in drug development.

BC Nature Discovery

The Clinical Pharmacology & Therapeutics publication describes how the Biomarkers Consortium works, highlights its accomplishments and explains its strategic expansion.


The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventative medicine and medical diagnostics.


The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient's illness or lifespan. Its goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.


Front Page: